Harrow (HROW) shares soared 8.4% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.8% gain over the past four weeks. Earlier this week, the company relaunched its ophthalmology drug, Triesence, which is approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. This might have driven the sha ...